UNSPSC 51171833: Bromopride

This classification denotes a dopamine antagonist and antiemetic agent with the molecular formula C14H22BrN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75473V2YZK, chemically known as o-anisamide, 4-amino-5-bromo-n-(2-(diethylamino)ethyl)- but generally known as bromopride, which bears US NIH Compound Identifier 2446. Bromopride most often comes in base and hydrochloride forms. European Medicines Agency schedules Bromopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05921MIG.

UNSPSC 51171833 Bromopride is a Commodity-code entry for a specific pharmaceutical agent, yet recent state and local opportunities tagged under this code show minimal relevant purchasing activity. The three recent solicitations linked to the code—Collin County's offender drug testing services RFP, the Texas HHS Commission's therapeutic pharmacy initiative RFI, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceuticals RFP—do not reflect direct procurement of bromopride itself. Collin County's RFP centers on specimen collection, laboratory testing infrastructure, and staffing for immunoassay and confirmatory testing services, not pharmaceutical supply; the Texas HHS RFI explores direct-to-manufacturer prescription fulfillment models and PBM alternatives without naming specific drugs; and the MMCAP RFP solicits generic and OTC product manufacturers across a broad therapeutic spectrum without bromopride in the named scope. The code appears to be a mismatch for the actual work being bought in these state and local markets.

State and local governments issuing under this code include county supervision and corrections departments (Collin County, Texas), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states (MMCAP, serving Minnesota, Oregon, and participating jurisdictions). Geographic activity is concentrated in Texas and the upper Midwest, with no clear pattern of bromopride-specific procurement. Unless bromopride figures in pharmacy benefit formularies or correctional healthcare supply chains that state procurement offices are tagging inconsistently, this code signals limited near-term opportunity for a vendor focused on that active pharmaceutical ingredient at the state and local level.